Cargando…

DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer

BACKGROUND: Colorectal cancer (CRC) is the third most commonly diagnosed human malignancy worldwide. Upregulation of inhibitory immune checkpoints by tumor-infiltrating immune cells (TIICs) or their ligands by tumor cells leads to tumor evasion from host immunosurveillance. Changes in DNA methylatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sasidharan Nair, Varun, Toor, Salman M., Taha, Rowaida Z., Shaath, Hibah, Elkord, Eyad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6080402/ https://www.ncbi.nlm.nih.gov/pubmed/30081950 http://dx.doi.org/10.1186/s13148-018-0539-3

Ejemplares similares

DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer
por: Sasidharan Nair, Varun, et al.
Publicado: (2018)

Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4(+) T Cells
por: Saleh, Reem, et al.
Publicado: (2019)

DNA methylation in the promoters of PD-L1, MMP9, ARG1, galectin-9, TIM-3, VISTA and TGF-β genes in HLA-DR(–) myeloid cells, compared with HLA-DR(+) antigen-presenting cells
por: Saleh, Reem, et al.
Publicado: (2020)

Blockade of PD-1, PD-L1, and TIM-3 Altered Distinct Immune- and Cancer-Related Signaling Pathways in the Transcriptome of Human Breast Cancer Explants
por: Saleh, Reem, et al.
Publicado: (2020)

Transcriptomic Analyses Revealed Systemic Alterations in Gene Expression in Circulation and Tumor Microenvironment of Colorectal Cancer Patients
por: Shaath, Hibah, et al.
Publicado: (2019)

Immune Co-inhibitory Receptors CTLA-4, PD-1, TIGIT, LAG-3, and TIM-3 in Upper Tract Urothelial Carcinomas: A Large Cohort Study
por: Jin, Shengming, et al.
Publicado: (2023)

Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023)

T‐cell responses and therapies against SARS‐CoV‐2 infection
por: Toor, Salman M., et al.
Publicado: (2020)

High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer
por: Mollavelioglu, Baran, et al.
Publicado: (2022)

PD-L1 Blockade by Atezolizumab Downregulates Signaling Pathways Associated with Tumor Growth, Metastasis, and Hypoxia in Human Triple Negative Breast Cancer
por: Saleh, Reem, et al.
Publicado: (2019)

Transcriptomic Profiling of Tumor-Infiltrating CD4(+)TIM-3(+) T Cells Reveals Their Suppressive, Exhausted, and Metastatic Characteristics in Colorectal Cancer Patients
por: Sasidharan Nair, Varun, et al.
Publicado: (2020)

Correction: Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023)

The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)
por: De Giglio, Andrea, et al.
Publicado: (2021)

Differential gene expression of tumor-infiltrating CD33(+) myeloid cells in advanced- versus early-stage colorectal cancer
por: Toor, Salman M., et al.
Publicado: (2020)

Identification of two HLA-A*0201 immunogenic epitopes of lactate dehydrogenase C (LDHC): potential novel targets for cancer immunotherapy
por: Thomas, Remy, et al.
Publicado: (2020)

Integrated whole transcriptome and small RNA analysis revealed multiple regulatory networks in colorectal cancer
por: Shaath, Hibah, et al.
Publicado: (2021)

Editorial of Harnessing the Power of T Cells: The Promising Hope for a Universal Influenza Vaccine
por: Toor, Salman M., et al.
Publicado: (2020)

Systemic levels of the soluble co-inhibitory immune checkpoints, CTLA-4, LAG-3, PD-1/PD-L1 and TIM-3 are markedly increased in basal cell carcinoma
por: Malinga, Nonkululeko Z., et al.
Publicado: (2022)

Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals malignancy
por: Takamatsu, Kimiharu, et al.
Publicado: (2021)

PD-L1 Expression in Human Breast Cancer Stem Cells Is Epigenetically Regulated through Posttranslational Histone Modifications
por: Darvin, Pramod, et al.
Publicado: (2019)

Tissue-Specific Expression of TIGIT, PD-1, TIM-3, and CD39 by γδ T Cells in Ovarian Cancer
por: Weimer, Pauline, et al.
Publicado: (2022)

Immune checkpoint inhibitors: recent progress and potential biomarkers
por: Darvin, Pramod, et al.
Publicado: (2018)

Role of Epigenetic Modifications in Inhibitory Immune Checkpoints in Cancer Development and Progression
por: Saleh, Reem, et al.
Publicado: (2020)

Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients
por: Marcq, Elly, et al.
Publicado: (2017)

The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma
por: Chen, Benjamin J., et al.
Publicado: (2019)

PD-L1, PD-1, LAG-3, and TIM-3 in Melanoma: Expression in Brain Metastases Compared to Corresponding Extracranial Tumors
por: Wang, Jaeyun Jane, et al.
Publicado: (2019)

CD4(+) T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART
por: Fromentin, Rémi, et al.
Publicado: (2016)

Immune Checkpoint Profiling in Humanized Breast Cancer Mice Revealed Cell-Specific LAG-3/PD-1/TIM-3 Co-Expression and Elevated PD-1/TIM-3 Secretion
por: Bruss, Christina, et al.
Publicado: (2023)

Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors
por: Natoli, Marina, et al.
Publicado: (2022)

The Search for an Interesting Partner to Combine with PD-L1 Blockade in Mesothelioma: Focus on TIM-3 and LAG-3
por: Marcq, Elly, et al.
Publicado: (2021)

Correction to: Metabolic reprogramming of T regulatory cells in the hypoxic tumor microenvironment
por: Sasidharan Nair, Varun, et al.
Publicado: (2021)

Metabolic reprogramming of T regulatory cells in the hypoxic tumor microenvironment
por: Sasidharan Nair, Varun, et al.
Publicado: (2021)

Expression of immune checkpoints and T cell exhaustion markers in early and advanced stages of colorectal cancer
por: Saleh, Reem, et al.
Publicado: (2020)

Long non-coding RNA (lncRNA) transcriptional landscape in breast cancer identifies LINC01614 as non-favorable prognostic biomarker regulated by TGFβ and focal adhesion kinase (FAK) signaling
por: Vishnubalaji, Radhakrishnan, et al.
Publicado: (2019)

Single-Cell Transcriptome Analysis Highlights a Role for Neutrophils and Inflammatory Macrophages in the Pathogenesis of Severe COVID-19
por: Shaath, Hibah, et al.
Publicado: (2020)

Transcriptomic Analyses of Myeloid-Derived Suppressor Cell Subsets in the Circulation of Colorectal Cancer Patients
por: Sasidharan Nair, Varun, et al.
Publicado: (2020)

Tumor-Infiltrating Lymphoid Cells in Colorectal Cancer Patients with Varying Disease Stages and Microsatellite Instability-High/Stable Tumors
por: Toor, Salman M., et al.
Publicado: (2021)

Addition of anti-TIM3 or anti-TIGIT Antibodies to anti-PD1 Blockade Augments Human T cell Adoptive Cell Transfer
por: Martinez, Marina, et al.
Publicado: (2021)

Increased coexpression of PD-L1 and TIM3/TIGIT is associated with poor overall survival of patients with esophageal squamous cell carcinoma
por: Wang, Peipei, et al.
Publicado: (2021)

Differential gene expression of tumor-infiltrating CD4(+) T cells in advanced versus early stage colorectal cancer and identification of a gene signature of poor prognosis
por: Sasidharan Nair, Varun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_c0oa475g1nl1erc440i5pfmfqu